All News

2019

September

Media Release / Sep 13, 2019

Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More
Media Release / Sep 13, 2019

New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

Read More
Media Release / Sep 10, 2019

Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

Read More
Media Release / Sep 09, 2019

Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine

Read More

August

Media Release / Aug 30, 2019

Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

Read More
Super-resolution techniques reveal tubulin proteins (purple) in a neuron.
Story / Aug 07, 2019

Using Super-Resolution Microscopy To See Neurodegeneration

Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.

Read More

July

Media Release / Jul 11, 2019

Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention

Read More
Janneke van der Kamp on the Novartis campus in Basel
Story / Jul 09, 2019

Flexibility at Novartis: Janneke van der Kamp

Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.

Read More
Media Release / Jul 02, 2019

Novartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)

Read More
Media Release / Jul 01, 2019

Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More